Evidence map›Paper›PMID 36253632›Full record

ReviewJournal of cancer research and clinical oncology2023

Role of smartphone devices in precision oncology.

Ruby Srivastava

Open access · greenAbstract readReview
In one paragraph

Review in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ruby SrivastavaCSIR-Centre for Cellular and Molecular Biology, Hyderabad, India. amitruby1@gmail.com.
Centre for Cellular and Molecular Biology · IN

Funding

Department of Science and Technology, New Delhi, India (SR/WOS-A/CS-69/2018)
6 · The paper itself

Abstract

backgroundTo improve the care for cancer patients, personalized treatment including monitoring and managing Quality of life (QoL) data collection of patients in his/her home environment, its integration and its analysis is necessary. Advanced technologies have been used to develop smartphone devices to support cancer patients and clinicians by integrating all patient-relevant data, helping with Patient Reported Outcomes (PRO), side effect management, appointments, and nutritional support. PURPOSE: In this review the role and challenges of using smartphone applications for precision oncology is discussed.

methodsThe methodology section includes the data collection, data integration and predictive modelling approaches. The design, development and evaluation of (AI/ML) algorithms of these apps need intended purpose of these algorithms, description of used mepthods, validity and appropriateness of the datasets, design of the algorithms, evaluation, implementation of these (AI/ML) algorithms and post treatment monitoring.

resultsThough Artificial intelligence (AI) based results showed higher diagnostic classification accuracy in most of the results, the advancement of these mobile apps technologies has a few limitations.

conclusionsML techniques and DL are used to discover novel biomarkers for early detection and diagnostics, and AI are used to accelerate drug discovery, exploit biomarkers to accurately match patients to clinical trials, and personalize cancer therapy based only on patient's own data. AI based smartphone apps cannot be treated as autonomous rather used as an integrative tool for patient-relevant data, PRO, side effect management, appointments, nutritional support, emotional and social support, severity of pain detection and correct diagnosis at higher level. It should encourage the clinicians and care givers to support and establish patient-physician relationships with the help of these apps.

Indexed as

NeoplasmsSmartphoneArtificial IntelligenceBiomarkersFemaleHumansMalePrecision MedicineQuality of LifeBiomarkersArtificial intelligenceMachine learningOncologyQuality of lifeSmartphones

Identifiers

PMID36253632
PMCPMC11796496
OpenAlexW4306411907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.